Vonoprazan/amoxicillin/clarithromycin

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori infection. It contains vonoprazan, a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.
It was approved for medical use in Japan in 2016, and in the United States in May 2022. The US Food and Drug Administration considers it to be a first-in-class medication.